1Helfrich MH, Evans DE, Grabowski PS, et al.Expression of nitric oxide synthase isoforms in bone and bone cell cultures. J Bone Miner Res, 1997,12: 1108-1112.
3Mancini L, Becherini L, Benvenuti S, et al. Bioeffects of a nitric oxide donor in a human preosteoclastic cell line. Int J Clin Pharmacol Res, 1997,17: 2-7.
4Macintyre I, Zaidi M, Alam AS, et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cycle GMP. Proc Natl Acad Sci USA, 1991,88: 2936-2940.
2Lalla S, Hothorn LA, Haag N, et al. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporosis Int, 1998,8:97-103.
3Raven P, Chistensen JO, Baumann M, et al. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment:prediction of bone mass changes during treatment. Bone, 1998,22:559-564.
4Schlosser K, Scigalla P. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest Suppl,1997,227:21-28.
10Caballero-Alías AM,Loveridge N,Lyon A,et al.NOS isoforms in adult human osteocytes:multiple pathways of NO regulation?[J].Calcif Tissue Int,2004,75(1):78-84.
